All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Tirzepatide Dose Conversion Chart

Switching between dose levels or starting a new tirzepatide prescription? Getting the tirzepatide dose conversion right is critical for safe, effective...

By FormBlends Editorial Research|Source reviewed by FormBlends Medical Team||

Source Reviewed

Written by FormBlends Editorial Research · Checked against primary sources by FormBlends Medical Team

Tirzepatide Dose Conversion Chart custom 2026 header image for GLP-1 Weight Loss
Custom header image for Tirzepatide Dose Conversion Chart, GLP-1 Weight Loss, and better treatment decision-making.
In This Article

This article is part of our GLP-1 Weight Loss collection. See also: Provider Comparisons | Peptide Guides

Search and AI answer brief

Practical answer: Tirzepatide Dose Conversion Chart

Switching between dose levels or starting a new tirzepatide prescription? Getting the tirzepatide dose conversion right is critical for safe, effective...

Short answer

Switching between dose levels or starting a new tirzepatide prescription? Getting the tirzepatide dose conversion right is critical for safe, effective...

Search intent

This page answers a specific GLP-1 Weight Loss question rather than a generic overview.

What to verify

semaglutide, tirzepatide, retatrutide, peptide evidence quality

How to use it

Use this information to prepare sharper questions for a licensed provider.

Key Takeaway

See your GLP-1 options in about 2 minutes. Free and private. See my options →

Switching between dose levels or starting a new tirzepatide prescription? Getting the tirzepatide dose conversion right is critical for safe, effective treatment. If you're stepping up from 2.

Switching between dose levels or starting a new tirzepatide prescription? Getting the tirzepatide dose conversion right is critical for safe, effective treatment. If you're stepping up from 2.5 mg to 5 mg or trying to figure out how many syringe units equal your prescribed dose, this guide and conversion chart have you covered.

Key Takeaways: - The Standard Tirzepatide Titration Schedule - Learn how to convert tirzepatide mg to syringe units - Tips for Accurate Tirzepatide Dosing - When to Talk to Your Provider About Dose Changes

Below you'll find the standard tirzepatide titration schedule, a step-by-step conversion process, and a reference chart you can bookmark or print.

The Standard Tirzepatide Titration Schedule

Like semaglutide, tirzepatide follows a gradual dose increase. You start low and step up over time. This reduces side effects and helps your body adjust to the medication's dual-action mechanism) tirzepatide activates both GIP and GLP-1 receptors.

The standard schedule looks like this:

  • Weeks 1-4: 2.5 mg once weekly
  • Weeks 5-8: 5 mg once weekly
  • Weeks 9-12: 7.5 mg once weekly
  • Weeks 13-16: 10 mg once weekly
  • Weeks 17-20: 12.5 mg once weekly
  • Week 21 onward: 15 mg once weekly

"What makes tirzepatide particularly interesting is the dual GIP/GLP-1 mechanism. We're seeing that GIP receptor activation appears to amplify the metabolic effects in ways we didn't fully anticipate from the preclinical data.", Dr. Ania Jastreboff, MD, PhD, Yale School of Medicine, lead author of SURMOUNT-1[1]

Not everyone reaches 15 mg. Your provider determines your target dose based on your response, tolerance, and goals. Many people achieve meaningful results at 5 mg or 10 mg.

Clinical trials showed that tirzepatide at the 15 mg dose led to average weight loss of approximately 22% of body weight over 72 weeks. But the 5 mg dose also showed significant results (approximately 15% average weight loss. More isn't always necessary.

How to Convert Tirzepatide mg to Syringe Units

If you're using compounded tirzepatide from a licensed 503A pharmacy, your medication comes in a vial at a specific concentration. Here's how to do the conversion. Check out our see real Zepbound results for detailed data.

GLP-1 Weight Loss Results by Medication Mean Body Weight Loss (%) 0 6 12 18 24 22 15 8 24 Tirzepatide Semaglutide Liraglutide Retatrutide Based on published STEP and SURMOUNT trial data
GLP-1 Weight Loss Results by Medication. Based on published STEP and SURMOUNT trial data.
View data table
Bar chart showing glp-1 weight loss results by medication: Tirzepatide (22), Semaglutide (15), Liraglutide (8), Retatrutide (24)
CategoryMean Body Weight Loss (%)Detail
Tirzepatide22~22% body weight at 72 wks
Semaglutide15~15% body weight at 68 wks
Liraglutide8~8% body weight at 56 wks
Retatrutide24~24% in Phase 2 trial
Illustration for Tirzepatide Dose Conversion Chart

The formula: Prescribed dose (mg) divided by vial concentration (mg/mL) = injection volume (mL)

Then multiply the mL by 100 to get units on a U-100 insulin syringe.


Free Download: Universal Peptide Dose Conversion Table A printable chart with pre-calculated conversions for tirzepatide and other peptides at common concentrations. Tape it to your fridge for quick reference. Get yours free) we'll email it to you instantly.

[Download CTA Button]


Example with a 10 mg/mL concentration:

Prescribed Dose Volume (mL) Syringe Units (U-100)
2.5 mg 0.25 mL 25 units
5 mg 0.50 mL 50 units
7.5 mg 0.75 mL 75 units
10 mg 1.00 mL 100 units

Example with a 20 mg/mL concentration:

Prescribed Dose Volume (mL) Syringe Units (U-100)
2.5 mg 0.125 mL 12.5 units
5 mg 0.25 mL 25 units
7.5 mg 0.375 mL 37.5 units
10 mg 0.50 mL 50 units
12.5 mg 0.625 mL 62.5 units
15 mg 0.75 mL 75 units

Notice how a higher concentration means smaller injection volumes. This is one reason pharmacies compound at different concentrations (a smaller injection can be more comfortable.

Always check your vial label before drawing your dose. If the concentration doesn't match what you expected, contact your provider or pharmacy before injecting.

You can also use the to run these numbers instantly.

Tips for Accurate Tirzepatide Dosing

Accuracy matters at every step of the process. Here are practical tips to make sure you're getting your full prescribed dose.

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.

Try the BMI Calculator →

Use the right syringe. For smaller volumes (under 0.3 mL), a 0.3 mL insulin syringe gives you finer markings and better accuracy. For larger volumes, a 1 mL syringe works well. Match your syringe to your injection volume.

Draw slowly. Pull the plunger back slowly and steadily. Rushing can introduce air bubbles, which take up space where medication should be.

Remove air bubbles. After drawing your dose, hold the syringe needle-up and tap the barrel gently. Any bubbles will rise to the top. Push the plunger slightly to expel the air, then verify your dose volume is still correct.

Be consistent with injection day and time. Tirzepatide is a once-weekly medication. Pick the same day each week. The can send you reminders so you never miss a dose.

Log every injection. Record your dose, injection site, and any side effects after each injection. This data helps your provider make informed decisions about dose adjustments. The make this simple.

When to Talk to Your Provider About Dose Changes

Dose adjustments should always come from your provider. But knowing when to bring it up can help you advocate for yourself.

You should reach out if you've been at your current dose for the recommended period with no significant side effects and want to discuss stepping up. Your provider may approve the increase or recommend staying put based on your progress.

You should also reach out if you're experiencing persistent side effects that haven't improved after 2-3 weeks at a new dose. Common side effects include nausea, constipation, and decreased appetite. Most are mild and temporary, but your provider can offer strategies to manage them. Check our for more detail.

Never adjust your dose on your own. Even if you have leftover medication at a different concentration, don't try to calculate a new dose yourself. Changes to your dosing should always go through your prescribing provider.

If you're exploring tirzepatide options, learn more about to understand which medication your provider might recommend.

Frequently Asked Questions

Can I split a tirzepatide dose across two injections?

This isn't standard practice. Tirzepatide is designed as a once-weekly single injection. If your injection volume feels too large, talk to your provider about whether a higher concentration formulation might be available to reduce the volume.

What happens if I miss a tirzepatide dose?

If you miss a dose and it's been less than 4 days (96 hours), take it as soon as you remember. If it's been more than 4 days, skip the missed dose and take your next dose on the regular day. Don't double up.

Why is my tirzepatide a different concentration than what I've seen online?

Compounding pharmacies prepare tirzepatide at various concentrations. Your pharmacy and provider chose a concentration that works for your prescribed dose and preferred injection volume. The actual medication is the same) the concentration just changes how many units you draw.

Do I need to reconstitute compounded tirzepatide?

It depends on the formulation. Some compounded tirzepatide comes pre-mixed and ready to inject. Others come as lyophilized powder that requires reconstitution calculator. Check with your pharmacy and follow the instructions provided with your medication.

Start your path Today

Every transformation starts with a single step. Talk to a licensed FormBlends provider about whether this approach is right for you, consultations are free and confidential.


Medical References

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
  2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
  3. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
  4. Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]

Sources &. References

  1. Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files. NCHS Data Brief. No. 492. CDC/NCHS. 2023.
  2. Sumithran P, Prendergast LA, Delbridge E, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med. 2011;365(17):1597-1604. Doi:10.1056/NEJMoa1105816
  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
  4. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
  5. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
  6. Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
  7. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563

The information in this article is intended for educational use only and shouldn't be considered medical advice. Consult a qualified healthcare provider before making any changes to your medication or supplement regimen. FormBlends helps with connections with licensed providers for personalized medical guidance.

Last updated: 2026-03-24

See your options in about 2 minutes

Take the free quiz and see what fits you. Quick, private, and no commitment to continue.

See my options →

Research Snapshot

Provider comparison
Page type
Provider comparison
FormBlends review
Last reviewed
2026-04-01
FormBlends review
Retatrutide evidence source
Official source
Semaglutide evidence source
Official source
Tirzepatide evidence source
Official source
Zepbound evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-04-01.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For Tirzepatide Dose Conversion Chart, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Randomized trialTirzepatide evidence2025

Tirzepatide for Obesity Treatment and Diabetes Prevention

Supports newer discussion of obesity treatment and diabetes-prevention outcomes.

PubMed

Systematic reviewGLP-1 class evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.

PubMed

Systematic reviewGLP-1 class evidence2025

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus

Used for pages discussing stopping therapy, weight regain, and long-term planning.

PubMed

Systematic reviewGLP-1 class evidence2025

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition

Supports body-composition, lean-mass, and metabolic-risk context.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Emerging pharmacotherapies for obesity: A systematic review

Broad context for new and established obesity-drug categories.

PubMed

ReviewObesity pharmacotherapy evidence2026

Glucagon-like receptor agonists and next-generation incretin-based medications

Current review for incretin-based obesity medications and cardiometabolic effects.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

Used as a class-level evidence anchor when no more specific citation group matches.

PubMed

GLP-1 decision path

Use this page to decide if a provider review is the right next step

Direct answer

Tirzepatide Dose Conversion Chart research is most useful when it helps you compare eligibility, expected results, side effects, cost, and the supervision needed before treatment.

Evidence check

The strongest GLP-1 pages connect the practical answer to clinical trials, FDA labeling where applicable, and real access constraints.

Safety check

A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation.

Next step

When the page matches your goal, continue into the FormBlends get-started flow so the intake can route you toward the right prescription review path.

FormBlends Editorial Context

Reviewed May 14, 2026

Switching between dose levels or starting a new tirzepatide prescription? Getting the tirzepatide dose conversion right is critical for safe, effective treatment. Whether you're stepping up from 2. Read "Tirzepatide Dose Conversion Chart" as a GLP-1 treatment guide where medication choice, dosing, side effects, monitoring, and insurance rules can change the decision. The main job of this page is dosing literacy and clinician follow-up, especially where the topic touches tirzepatide, dosing. Because this article has 7 major sections, scan the headings first and then use the FAQ or summary sections to pressure-test the answer. Use it to ask sharper questions of a licensed clinician, not as a substitute for personal medical advice.

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for Tirzepatide Dose Conversion Chart

For this glp-1 weight loss page, the 2026 refresh focuses on semaglutide, tirzepatide, retatrutide, safety signals, dose, conversion so the article stays close to the question behind "Tirzepatide Dose Conversion Chart".

The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate Tirzepatide Dose Conversion Chart from nearby GLP-1, peptide, hormone, or provider-comparison searches.

Readers can use the added context to bring sharper questions to a licensed provider before making a treatment, cost, or care decision.

Tirzepatide Dose Conversion Chart custom 2026 image for glp-1 weight loss on FormBlends

Custom 2026 image for Tirzepatide Dose Conversion Chart, glp-1 weight loss, and better treatment decision-making.

Image description: Unique image for this page covering Tirzepatide Dose Conversion Chart, glp-1 weight loss, safety, cost, provider selection, and patient decision-making.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.